Isobutyric acid
|
Basic information |
| Metabolite name | Isobutyric acid |
 | HMDB0001873 |
 |
C02632 |
 |
6590 |
| Synonyms | Isobutyrate |
| No. of studies | 26 |
|
Basic information |
| Metabolite name | Isobutyric acid |
| HMDB0001873 |
|
C02632 |
|
6590 |
| Synonyms | Isobutyrate |
| No. of studies | 26 |
|
Relationship between Isobutyric acid and depression (count: 26) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M058 | Type1 | depressed HBV-infected patients group vs. control group and non-depressed HBV-infected group | Urine | Human | Up |
| Study M097 | Type1 | depressed men group vs. control men group | Urine | Human | Up |
| Study M097 | Type1 | depressed women group vs. control women group | Urine | Human | Up |
| Study M1009 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M1009 | Type2 | CUMS + multi-probiotics group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M1016 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M1016 | Type2 | CUMS + ginsenoside Rh4 group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M1016 | Type2 | CUMS + imipramine group vs. CUMS group | Faece | C57BL/6J mouse | Up |
| Study M1019 | Type1 | depression group vs. control group | Serum | Human | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Up |
| Study M1026 | Type2 | CUMS + Bacillus licheniformis group vs. CUMS group | Faece | Sprague-Dawley rat | Up |
| Study M1027 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | Wistar rat | Up |
| Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
| Study M1097 | Type1 | placebo-treated depression group vs. control group | Faece | Human | Up |
| Study M1127 | Type2 | flavonoid-low orange cordial group, after 8-week treatment vs. baseline | Faece | Human | Up |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Up |
| Study M577 | Type1 | male depression group vs. male control group, aged 30-39 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 20-29 | Urine | Human | Unknown |
| Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Urine | Human | Unknown |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M706 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M706 | Type2 | CUMS + CCFM1025 group vs. CUMS group | Faece | C57BL/6 mouse | Up |
| Study M708 | Type1 | CUMS group vs. control group | Faece | C57BL/6J mouse | Down |
| Study M886 | Type2 | lead-exposed + probiotics group vs. lead-exposed group | Faece | Sprague-Dawley rat | Up |
| Study M900 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M900 | Type2 | CUMS + Semen Sojae Praeparatum group vs. CUMS group | Faece | Sprague-Dawley rat | Down |
| Study M901 | Type1 | LPS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M905 | Type1 | subclinical depression group vs. control group | Urine | Human | Down |
| Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M934 | Type1 | CUS + high-fat diet group vs. control group | Serum | C57BL/6J mouse | Down |
| Study M934 | Type2 | CUS + high-fat diet + 5-hydroxytryptophan group vs. CUS + high-fat diet group | Serum | C57BL/6J mouse | Up |
| Study M934 | Type3 | control + 5-hydroxytryptophan group vs. control group | Serum | C57BL/6J mouse | Up |
| Study M967 | Type1 | bilateral common carotid artery occlusion group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M985 | Type2 | CUMS + indole acetic acid group vs. CUMS group | Cecum | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + paroxetine group vs. CRS group | Faece | C57BL/6J mouse | Up |
| Study M999 | Type2 | CRS + high dose of neoagaro-oligosaccharides group vs. CRS group | Faece | C57BL/6J mouse | Up |